Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.43 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL19259428 | 0.98 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNA7MEN1CYP2D6 | |
| SCHEMBL978739 | 0.94 | MEN1 (0.45) | CHRNB2CHRNA4CHRNA7MEN1CYP2D6 | |
| SCHEMBL7750646 | 0.79 | — | — | |
| SCHEMBL18903009 | 0.79 | — | — | |
| SCHEMBL787918 | 0.78 | CHRM2 (0.39) | CHRM3CHRM2CHRM1 | |
| Hydrochloric Acid SCHEMBL4573925 | 0.77 | CHRM2 (0.38) | CHRM3CHRM2CHRM1 | |
| SCHEMBL8600489 | 0.75 | BAZ2A (0.37) | — | |
| SCHEMBL11131656 | 0.74 | HTR2C (0.38) | CYP2D6CHRM3CHRM2CHRM1 | |
| SCHEMBL4005386 | 0.73 | CHRM2 (0.41) | CHRM3CHRM2CHRM1 | |
| SCHEMBL3923660 | 0.72 | SCN9A (0.39) | CHRNB2CHRNA4CHRNA7POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113423427-A | IRAK degrading agents and uses thereof | 凯麦拉医疗公司 | 2021-09-21 | — | — | CN | disclosed |
| EP-3594203-B1 | SUBSTITUTED PYRROLIDINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2021-08-04 | — | — | EP | disclosed |
| US-11059780-B2 | Substituted pyrrolidine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-07-13 | — | — | US | disclosed |
| CN-112105385-A | IRAK degrading agents and uses thereof | 凯麦拉医疗公司 | 2020-12-18 | — | — | CN | disclosed |
| US-20200385345-A1 | SUBSTITUTED PYRROLIDINE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-12-10 | — | — | US | disclosed |
| CN-103635472-B | Serine/threonine kinase inhibitor | 阵列生物制药公司 | 2018-01-12 | — | — | CN | disclosed |
| EP-2763535-B1 | AZAINDOLES AS JANUS KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2017-06-07 | — | — | EP | disclosed |
| US-9133187-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9096598-B2 | Azaindoles as Janus kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-08-04 | — | — | US | disclosed |
| EP-2681215-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2015-04-22 | — | — | EP | disclosed |
| EP-2051980-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | Brystol-Myers Squibb Company (US) | 2009-04-29 | — | — | EP | disclosed |
| WO-2008128647-A1 | QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | WO | disclosed |
| CN-101247804-A | chemical compound | SMITHKLINE BEECHAM CORP (US) | 2008-08-20 | — | — | CN | disclosed |
| WO-2008067481-A1 | AZA-INDOLYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2008-06-05 | — | — | WO | disclosed |
| EP-1896014-A2 | CHEMICAL COMPOUNDS | Smithkline Beecham Corporation (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2008024724-A1 | AZA-BENZOTHIOPHENYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008024725-A1 | AZA-BENZOFURANYL COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008021924-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080045496-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
| WO-2007005534-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059780-B2 | Substituted pyrrolidine compound and use thereof | HCRTR2, HCRTR1, CRHR2 | CHRNB2 312/4885CHRNA4 172/4885CHRNA7 201/4885 |
| US-20200385345-A1 | SUBSTITUTED PYRROLIDINE COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, CRHR2 | CHRNB2 312/4885CHRNA4 172/4885CHRNA7 201/4885 |
| US-20080045496-A1 | PYRROLOTRIAZINE KINASE INHIBITORS | JAK2, NTRK2, NTRK3 | CHRNB2 2180/4885CHRNA4 2057/4885CHRNA7 1622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.